Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Inclusion Criteria

• World Health Organization (WHO)/ECOG performance status of 0 or 1
• Body weight >30 kg at enrollment and treatment assignment
• At least 1 measurable lesion, not previously irradiated
• No prior exposure to immune-mediated therapy (including therapeutic anticancer vaccines)
• For patients with oropharyngeal HNSCC HPV status has to be known

Exclusion Criteria

• Patients with simultaneous primary malignancies or bilateral tumors
• Active or prior documented autoimmune or inflammatory disorders
• Brain metastases or spinal cord compression
• Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV; positive HIV 1/2 antibodies)
• Has a paraneoplastic syndrome (PNS) of autoimmune nature
• HNSCC cohort: Head and neck cancer that does not include unresectable, locally advanced cancer of oral cavity, larynx, oropharynx or hypopharynx. HNSCC of unknown primary are also excluded
• NSCLC and SCLC cohort: Mixed SCLC and NSCLC histology
• SCLC cohort: Extensive-stage SCLC